Development of extended-release solid dispersion granules of tacrolimus

Evaluation of release mechanism and human oral bioavailability

Daisuke Tsunashima, Kazunari Yamashita, Ken ichi Ogawara, Kazuhiro Sako, Tadashi Hakomori, Kazutaka Higaki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: We aimed to prepare a once-daily modified-release oral formulation of tacrolimus by utilizing an extended-release granules (ERG). Methods: Extended-release granules were prepared using ethylcellulose (EC), hydroxypropylmethylcellulose (HPMC) and lactose via a solvent evaporation method with ethanol. Physicochemical and biopharmaceutical studies were performed to determine the formulation with optimum release profile of tacrolimus from ERG. Key findings: Tacrolimus existed in an amorphous state in ERG. Tacrolimus release from ERG was attenuated by EC and facilitated by lactose, suggesting that drug release kinetics could adequately be regulated by these components. Those release profiles were consistent with Higuchi's equation, suggesting a diffusion-type release mechanism. Smooth surface of ERG changed to the structure with pores after the release test, likely derived from the dissolution of HPMC and lactose. But ERG structure formed by EC was still maintained after the release test, leading to the longer maintenance of diffusion-type release. Two ERG formulations selected by blood concentration simulation successfully provided long-term retention of tacrolimus in blood in a human absorption study. Conclusions: We successfully developed the formulation exhibiting a significant reduction in Cmax, the longer mean residence time and AUC close to that of an immediate-release tacrolimus formulation, being preferred from the viewpoint of safe and effective immunosuppressant pharmacotherapy.

Original languageEnglish
JournalJournal of Pharmacy and Pharmacology
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Tacrolimus
Biological Availability
Lactose
Immunosuppressive Agents
Area Under Curve
Ethanol
Pharmacokinetics
Maintenance
Drug Therapy
ethyl cellulose

Keywords

  • Controlled and sustained release systems
  • Pharmaceutics and drug delivery

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Development of extended-release solid dispersion granules of tacrolimus : Evaluation of release mechanism and human oral bioavailability. / Tsunashima, Daisuke; Yamashita, Kazunari; Ogawara, Ken ichi; Sako, Kazuhiro; Hakomori, Tadashi; Higaki, Kazutaka.

In: Journal of Pharmacy and Pharmacology, 2017.

Research output: Contribution to journalArticle

@article{cf2965cc1bea40129b692c71a91c4f64,
title = "Development of extended-release solid dispersion granules of tacrolimus: Evaluation of release mechanism and human oral bioavailability",
abstract = "Objectives: We aimed to prepare a once-daily modified-release oral formulation of tacrolimus by utilizing an extended-release granules (ERG). Methods: Extended-release granules were prepared using ethylcellulose (EC), hydroxypropylmethylcellulose (HPMC) and lactose via a solvent evaporation method with ethanol. Physicochemical and biopharmaceutical studies were performed to determine the formulation with optimum release profile of tacrolimus from ERG. Key findings: Tacrolimus existed in an amorphous state in ERG. Tacrolimus release from ERG was attenuated by EC and facilitated by lactose, suggesting that drug release kinetics could adequately be regulated by these components. Those release profiles were consistent with Higuchi's equation, suggesting a diffusion-type release mechanism. Smooth surface of ERG changed to the structure with pores after the release test, likely derived from the dissolution of HPMC and lactose. But ERG structure formed by EC was still maintained after the release test, leading to the longer maintenance of diffusion-type release. Two ERG formulations selected by blood concentration simulation successfully provided long-term retention of tacrolimus in blood in a human absorption study. Conclusions: We successfully developed the formulation exhibiting a significant reduction in Cmax, the longer mean residence time and AUC close to that of an immediate-release tacrolimus formulation, being preferred from the viewpoint of safe and effective immunosuppressant pharmacotherapy.",
keywords = "Controlled and sustained release systems, Pharmaceutics and drug delivery",
author = "Daisuke Tsunashima and Kazunari Yamashita and Ogawara, {Ken ichi} and Kazuhiro Sako and Tadashi Hakomori and Kazutaka Higaki",
year = "2017",
doi = "10.1111/jphp.12804",
language = "English",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",

}

TY - JOUR

T1 - Development of extended-release solid dispersion granules of tacrolimus

T2 - Evaluation of release mechanism and human oral bioavailability

AU - Tsunashima, Daisuke

AU - Yamashita, Kazunari

AU - Ogawara, Ken ichi

AU - Sako, Kazuhiro

AU - Hakomori, Tadashi

AU - Higaki, Kazutaka

PY - 2017

Y1 - 2017

N2 - Objectives: We aimed to prepare a once-daily modified-release oral formulation of tacrolimus by utilizing an extended-release granules (ERG). Methods: Extended-release granules were prepared using ethylcellulose (EC), hydroxypropylmethylcellulose (HPMC) and lactose via a solvent evaporation method with ethanol. Physicochemical and biopharmaceutical studies were performed to determine the formulation with optimum release profile of tacrolimus from ERG. Key findings: Tacrolimus existed in an amorphous state in ERG. Tacrolimus release from ERG was attenuated by EC and facilitated by lactose, suggesting that drug release kinetics could adequately be regulated by these components. Those release profiles were consistent with Higuchi's equation, suggesting a diffusion-type release mechanism. Smooth surface of ERG changed to the structure with pores after the release test, likely derived from the dissolution of HPMC and lactose. But ERG structure formed by EC was still maintained after the release test, leading to the longer maintenance of diffusion-type release. Two ERG formulations selected by blood concentration simulation successfully provided long-term retention of tacrolimus in blood in a human absorption study. Conclusions: We successfully developed the formulation exhibiting a significant reduction in Cmax, the longer mean residence time and AUC close to that of an immediate-release tacrolimus formulation, being preferred from the viewpoint of safe and effective immunosuppressant pharmacotherapy.

AB - Objectives: We aimed to prepare a once-daily modified-release oral formulation of tacrolimus by utilizing an extended-release granules (ERG). Methods: Extended-release granules were prepared using ethylcellulose (EC), hydroxypropylmethylcellulose (HPMC) and lactose via a solvent evaporation method with ethanol. Physicochemical and biopharmaceutical studies were performed to determine the formulation with optimum release profile of tacrolimus from ERG. Key findings: Tacrolimus existed in an amorphous state in ERG. Tacrolimus release from ERG was attenuated by EC and facilitated by lactose, suggesting that drug release kinetics could adequately be regulated by these components. Those release profiles were consistent with Higuchi's equation, suggesting a diffusion-type release mechanism. Smooth surface of ERG changed to the structure with pores after the release test, likely derived from the dissolution of HPMC and lactose. But ERG structure formed by EC was still maintained after the release test, leading to the longer maintenance of diffusion-type release. Two ERG formulations selected by blood concentration simulation successfully provided long-term retention of tacrolimus in blood in a human absorption study. Conclusions: We successfully developed the formulation exhibiting a significant reduction in Cmax, the longer mean residence time and AUC close to that of an immediate-release tacrolimus formulation, being preferred from the viewpoint of safe and effective immunosuppressant pharmacotherapy.

KW - Controlled and sustained release systems

KW - Pharmaceutics and drug delivery

UR - http://www.scopus.com/inward/record.url?scp=85028811773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028811773&partnerID=8YFLogxK

U2 - 10.1111/jphp.12804

DO - 10.1111/jphp.12804

M3 - Article

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

ER -